G20 World Brain Mapping & Therapeutic Scientific Summit

THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS

Retrieved on: 
Tuesday, September 26, 2023
Pancreatic cancer, Drug development, Chief Medical Advisor to the President, Oncolytics Biotech, Progression-free survival, Pancreatic Cancer Action Network, Clinical trial, Therapy, AB, Hope, Fast Track, MBA, Research, FOLFIRINOX, RNA, Progress, Doctor of Philosophy, Plasma protein binding, Science, ONC, G20 World Brain Mapping & Therapeutic Scientific Summit, Community, Patient, SAN, Vutrisiran, Cancer, TSX, Neoplasm, FDA, Gemcitabine, Safety, Disease, Pharmaceutical industry

BOSTON and SAN DIEGO and CALGARY, AB, Sept. 26, 2023 /PRNewswire/ -- In an effort to continue accelerating new treatment options for people with pancreatic cancer, the Pancreatic Cancer Action Network (PanCAN) today announced Oncolytics Biotech, Inc. (NASDAQ: ONCY) (TSX: ONC) as the recipient of its second annual PanCAN Therapeutic Accelerator Award. Oncolytics received this award in recognition of its promising work on pelareorep, an investigational immunotherapy treatment that introduces double-stranded RNA into cancer cells, which stimulates anticancer inflammatory effects, including innate and adaptive immune responses and the activation and recruitment of T cells into the tumor. This $5 million grant will enable Oncolytics to continue the next stage of its research focused on a clinical trial with Oncolytics' proprietary reovirus pelareorep in combination with modified FOLFIRINOX chemotherapy with or without an immune checkpoint inhibitor. If results are encouraging, the treatment combination may be advanced to late-stage clinical development through the PanCAN Precision PromiseSM adaptive clinical trial platform.

Key Points: 
  • If results are encouraging, the treatment combination may be advanced to late-stage clinical development through the PanCAN Precision PromiseSM adaptive clinical trial platform.
  • Testing pelareorep in combination with FOLFIRINOX expands the approach so all patients with advanced pancreatic cancer could have the opportunity to benefit from this innovative immunotherapeutic approach.
  • Oncolytics was selected to receive the 2023 PanCAN Therapeutic Accelerator Award for $5 million through a rigorous, competitive process involving scientific, business and programmatic review from leading experts in the field.
  • The funding offered through the PanCAN Therapeutic Accelerator Award represents an innovative and groundbreaking way for a non-profit to accelerate drug development.

THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS

Retrieved on: 
Tuesday, September 26, 2023
Pancreatic cancer, Drug development, Chief Medical Advisor to the President, Oncolytics Biotech, Progression-free survival, Pancreatic Cancer Action Network, Clinical trial, Therapy, AB, Hope, Fast Track, MBA, Research, FOLFIRINOX, RNA, Progress, Doctor of Philosophy, Precision, Plasma protein binding, Science, ONC, G20 World Brain Mapping & Therapeutic Scientific Summit, Community, Patient, SAN, Vutrisiran, Cancer, TSX, Neoplasm, FDA, Gemcitabine, Safety, Disease, Pharmaceutical industry

BOSTON, SAN DIEGO, and CALGARY, AB, Sept. 26, 2023 /PRNewswire/ -- In an effort to continue accelerating new treatment options for people with pancreatic cancer, the Pancreatic Cancer Action Network (PanCAN) today announced Oncolytics Biotech, Inc. (NASDAQ: ONCY) (TSX: ONC) as the recipient of its second annual PanCAN Therapeutic Accelerator Award. Oncolytics received this award in recognition of its promising work on pelareorep, an investigational immunotherapy treatment that introduces double-stranded RNA into cancer cells, which stimulates anticancer inflammatory effects, including innate and adaptive immune responses and the activation and recruitment of T cells into the tumor. This $5 million grant will enable Oncolytics to continue the next stage of its research focused on a clinical trial with Oncolytics' proprietary reovirus pelareorep in combination with modified FOLFIRINOX chemotherapy with or without an immune checkpoint inhibitor. If results are encouraging, the treatment combination may be advanced to late-stage clinical development through the PanCAN Precision PromiseSM adaptive clinical trial platform.

Key Points: 
  • If results are encouraging, the treatment combination may be advanced to late-stage clinical development through the PanCAN Precision PromiseSM adaptive clinical trial platform.
  • Testing pelareorep in combination with FOLFIRINOX expands the approach so all patients with advanced pancreatic cancer could have the opportunity to benefit from this innovative immunotherapeutic approach.
  • Oncolytics was selected to receive the 2023 PanCAN Therapeutic Accelerator Award for $5 million through a rigorous, competitive process involving scientific, business and programmatic review from leading experts in the field.
  • The funding offered through the PanCAN Therapeutic Accelerator Award represents an innovative and groundbreaking way for a non-profit to accelerate drug development.

THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS

Retrieved on: 
Tuesday, September 26, 2023
Pancreatic cancer, Drug development, Chief Medical Advisor to the President, Oncolytics Biotech, Progression-free survival, Pancreatic Cancer Action Network, Clinical trial, Therapy, AB, Hope, Fast Track, MBA, Research, FOLFIRINOX, RNA, Progress, Doctor of Philosophy, Precision, Plasma protein binding, Science, ONC, G20 World Brain Mapping & Therapeutic Scientific Summit, Community, Patient, SAN, Vutrisiran, Cancer, TSX, Neoplasm, FDA, Gemcitabine, Safety, Disease, Pharmaceutical industry

BOSTON, SAN DIEGO, and CALGARY, AB, Sept. 26, 2023 /PRNewswire/ -- In an effort to continue accelerating new treatment options for people with pancreatic cancer, the Pancreatic Cancer Action Network (PanCAN) today announced Oncolytics Biotech, Inc. (NASDAQ: ONCY) (TSX: ONC) as the recipient of its second annual PanCAN Therapeutic Accelerator Award. Oncolytics received this award in recognition of its promising work on pelareorep, an investigational immunotherapy treatment that introduces double-stranded RNA into cancer cells, which stimulates anticancer inflammatory effects, including innate and adaptive immune responses and the activation and recruitment of T cells into the tumor. This $5 million grant will enable Oncolytics to continue the next stage of its research focused on a clinical trial with Oncolytics' proprietary reovirus pelareorep in combination with modified FOLFIRINOX chemotherapy with or without an immune checkpoint inhibitor. If results are encouraging, the treatment combination may be advanced to late-stage clinical development through the PanCAN Precision PromiseSM adaptive clinical trial platform.

Key Points: 
  • If results are encouraging, the treatment combination may be advanced to late-stage clinical development through the PanCAN Precision PromiseSM adaptive clinical trial platform.
  • Testing pelareorep in combination with FOLFIRINOX expands the approach so all patients with advanced pancreatic cancer could have the opportunity to benefit from this innovative immunotherapeutic approach.
  • Oncolytics was selected to receive the 2023 PanCAN Therapeutic Accelerator Award for $5 million through a rigorous, competitive process involving scientific, business and programmatic review from leading experts in the field.
  • The funding offered through the PanCAN Therapeutic Accelerator Award represents an innovative and groundbreaking way for a non-profit to accelerate drug development.

Deepcell Expands Adoption of AI-Powered Morphology Characterization for Biological Researchers, Announces UCSF and TGen as First Installations in Technology Access Program

Retrieved on: 
Tuesday, November 1, 2022
Software, Research, Oncology, Data Management, Technology, Artificial Intelligence, Genetics, Science, Biotechnology, Stem Cells, Other Science, Health, RNA, Hearing, Translational Genomics Research Institute, Breast cancer, G20 World Brain Mapping & Therapeutic Scientific Summit, IMA, Newcastle University, Research, Industry, TAP, Computational biology, Program, Disease, Proteome, Eye, Biophysics, Cell, Pathology, AI, Molecular biology, Bias, Cell biology, Technology, Adoption, University, Deep learning, Biochemistry, Transcriptome, Melanoma, Associate, University of California, San Francisco, B cell, City, Patient, UCSF, Medical laboratory, Genome, Biology, FCCF, City of Hope, Tumor microenvironment, CA, Mobile phone, Pharmaceutical industry, Medical imaging, Microscope

Using Deepcell technology, we aim to study time-course morphological changes in drugged lymphoblast cells.

Key Points: 
  • Using Deepcell technology, we aim to study time-course morphological changes in drugged lymphoblast cells.
  • Dr. Mark Magbanua, Laboratory Medicine at UCSF said, "We are excited to be a part of the technology access program to test Deepcell's platform.
  • Its exciting to begin operating the instrument in-house at TGen as a part of the Technology Access Program.
  • Scientists interested in hearing more about Deepcell technology or incorporating the Deepcell technology into their grants can reach out to Deepcell directly at: [email protected] .

Bioasis Announces Publication Validating its xB³ ™ Platform Technology for CNS Therapeutics

Retrieved on: 
Thursday, June 3, 2021
Branches of biology, Neuroscience, Central nervous system disease, Neurological disorder, Neurology, Blood-Spinal Cord Barrier, G20 World Brain Mapping & Therapeutic Scientific Summit

Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3 platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases.

Key Points: 
  • Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3 platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases.
  • The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders.
  • The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.
  • For more information about the Company, please visit www.bioasis.us .

Bioasis Announces Publication of CNS Delivery of siRNA via xB³ ™ Platform Technology

Retrieved on: 
Monday, March 29, 2021
Branches of biology, Neuroscience, Central nervous system disease, Neurological disorder, Neurology, Blood-Spinal Cord Barrier, G20 World Brain Mapping & Therapeutic Scientific Summit

Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3 platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases.

Key Points: 
  • Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3 platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases.
  • The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders.
  • The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.
  • For more information about the Company, please visit www.bioasis.us .

Global Opinion Leaders from G20 Nations Urge Japanese Prime Minister Shinzo Abe to Establish Aging, Lifelong Brain Health, and Dementia as Central Pillars of G20 Agenda

Retrieved on: 
Thursday, March 21, 2019
G20, World, Organizations, Economy, G20 World Brain Mapping & Therapeutic Scientific Summit

There is an emerging scientific consensus that we all can take proactive, preventative actions to improve brain health across the lifespan.

Key Points: 
  • There is an emerging scientific consensus that we all can take proactive, preventative actions to improve brain health across the lifespan.
  • Prime Minister Abe, as this year's global G20 host, is in the perfect position to accomplish this."
  • At the G20 summit this year, Prime Minister Abe should underscore the importance biomarkers and innovative trial design will play in future clinical trials."
  • We will continue to insist that global leaders prioritize Alzheimer's and brain health at this year's G20 summit in Osaka and beyond."